• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • Blog
  • Free Resources
RevistaLab

RevistaLab

  • About
    • Meet Revista
    • Partners
    • Press
    • Sponsorship
    • Contact Us
  • Events
  • Why Subscribe?
    • Subscriptions
    • Business Development
    • Underwriting & Due Diligence
    • Development
    • Asset Management
    • Leasing
  • SUBSCRIBER LOGIN
Home / Rising Leaders Council / Mark Scaringi

Mark Scaringi

Vice President, Healthcare Finance, CIT Bank

Mark Scaringi is a Vice President in the Healthcare Finance group at CIT Bank (NYSE: CIT).  His responsibilities include underwriting healthcare real estate transactions with a primary focus in the medical office industry.  Mark’s experience includes structuring and underwriting real estate loans, accounts receivable revolving lines of credit, and cash flow financings.  Working across the healthcare spectrum, he has worked with clients including medical office building investors, skilled nursing facility and senior housing owners and operators, general acute care & long-term care hospitals, inpatient rehab facilities, and many others.  Prior to CIT Bank, Mark was an Originations Associate at Greystone & Co. where he was responsible for structuring senior and mezzanine loans for Greystone’s bridge platform.  Prior thereto, Mr. Scaringi was an Investment Associate at Sector Financial Inc. where he was responsible for underwriting revolving lines of credit, real estate secured term loans, and senior credit facilities to a wide range of healthcare companies.  Mark began his career with Capital One (NYSE: COF) in the healthcare finance group. There he served in several portfolio management roles and as an underwriter on the healthcare real estate team. Mark graduated from the University of Maryland, College Park with a B.S. degree in Accounting.

Ready to Schedule a Demo?

Get in Touch Now
  • Why Subscribe?
  • Events
  • The LAB Report
  • Add A Life Science Directory Listing
  • Contact Us
  • Sponsorship
  • About
  • Terms of Use
  • Press

SIGN UP FOR LAB REPORT NEWSLETTER

  • Twitter
  • Facebook
  • LinkedIn